Bibliografia
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44
Zahid I, Sharif S, Routledge T, Scarci M. What is the best way to diagnose and stage malignant pleural mesothelioma? Interact CardioVasc Thorac Surg 2011; 12: 254-9
Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009: CD001288
Zanazzi C, Hersmus R, Veltman IM, et al. Gene expression profiling and gene copy-number changes in malignant mesothelioma cell lines. Genes Chromosomes Cancer 2007; 46: 895-908
Wang ZJ, Reddy GP, Gotway MB, et al. Malignant Pleural Mesothelioma: Evaluation with CT, MR Imaging, and PET. RadioGraphics 2004; 24: 105-19
Zauderer MG, Krug LM. The Evolution of Multimodality Therapy for Malignant Pleural Masothelioma. Current Treatment Options in Oncology 2011; 12: 163-72
Whitaker D. The cytology of malignant mesothelioma. Cytopathology 2000; 11: 139-51 Win T, Lambrou T, Hutton BF, et al. 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging 2012; 39: 521-8 World Health Organization. Air Quality Guidelines, Geneva, 2000 (updating, 2012). www.ispesl.it/amianto/ amianto/analisi/analisi.htm. Ultima consultazione: giugno 2012 Yamaoka N, Kawasaki Y, Xu Y, et al. Establishment of in vivo fluorescence imaging in mouse models of malignant mesothelioma. Int J Oncol 2010; 37: 273-9 Yanagihara K, Tsumuraya M, Takigahira M, et al. An orthotopic implantation mouse model of human malignant pleural mesothelioma for in vivo photon counting analysis and evaluation of the effect of S-1 therapy. Int J Cancer 2010; 126: 2835-46 Yildirim H, Metintas M, Entok E, et al. Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related Benign Pleural Disease An Observational Pilot Study. J Thoracic Oncol 2009; 4: 1480-4
Zimling ZG, Sørensen JB, Gerds TA, et al. Low ERCC1 expression in malignant pleural mesotheliomas treated with cisplatin and vinorelbine predicts prolonged progression-free survival. J Thorac Oncol 2012; 7: 249-56 Zona A, Bruno C. Health surveillance for subjects with past exposure to asbestos: from international experience and Italian regional practices to a proposed operational model. Ann Ist Super Sanità 2009; 45: 147-61 Zoppoli L, Natullo G, Pascucci P. Le nuove regole per la salute e la sicurezza dei lavoratori. 2a edizione. Milano: Ipsoa, 2010 Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 2011; 37: 543-58 Zucali PA, Giovannetti E, Destro A, et al. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 2011; 17: 2581-90 Zucali PA, Simonelli M, Michetti G, et al. Secondline chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012; 75: 360-7
199